Showing results (241-250 of 264) with videos related to
Sort By:
Pageof 27
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.Trials|September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials unitsSharon B Love, Fay Cafferty, Claire Snowdon, et al.Cancer Cell|November 22, 2024
Elucidating acquired PARP inhibitor resistance in advanced prostate cancerGeorge Seed, Nick Beije, Wei Yuan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized TrialsTing Martin Ma, Yilun Sun, Shawn Malone, et al.Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancerAndrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 3, 2014
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicityGillian C Barnett, Deborah Thompson, Laura Fachal, et al.European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeJan Bogaerts, Matthew R Sydes, Nicola Keat, et al.Pageof 27